FMR LLC Cuts PTC Therapeutics Stake to 2.404%
Ticker: PTCT · Form: SC 13G/A · Filed: Jan 10, 2024 · CIK: 1070081
Complexity: simple
Sentiment: bearish
Topics: institutional-ownership, stake-reduction, investor-sentiment
TL;DR
**FMR LLC just dumped a chunk of PTC Therapeutics shares, now holding only 2.404%.**
AI Summary
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have significantly reduced their stake in PTC Therapeutics Inc. As of January 10, 2024, their beneficial ownership dropped to 1,814,421 shares, representing only 2.404% of the common stock. This is a notable decrease from their previous holdings, indicating a potential shift in their investment strategy or a re-evaluation of PTC Therapeutics' future prospects, which could signal a lack of confidence to current and prospective shareholders.
Why It Matters
This reduction by a major institutional investor like FMR LLC could signal a lack of confidence in PTC Therapeutics, potentially leading to negative investor sentiment and downward pressure on the stock price.
Risk Assessment
Risk Level: medium — A significant reduction in ownership by a major institutional investor like FMR LLC can indicate potential concerns about the company's future, posing a medium risk to current shareholders.
Analyst Insight
A smart investor would investigate the reasons behind FMR LLC's reduced stake and consider if this signals a fundamental shift in PTC Therapeutics' outlook before making any investment decisions.
Key Numbers
- 1,814,421 — Shares Beneficially Owned (Represents the total number of PTC Therapeutics common shares FMR LLC and Abigail P. Johnson now beneficially own.)
- 2.404% — Percent of Class (Indicates the reduced percentage of PTC Therapeutics' common stock held by FMR LLC and Abigail P. Johnson, signaling a significant decrease in their stake.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, principal owner of FMR LLC
- PTC THERAPEUTICS, INC. (company) — subject company, issuer of the common stock
- 1,814,421 (dollar_amount) — number of shares beneficially owned by FMR LLC and Abigail P. Johnson
- 2.404% (dollar_amount) — percentage of class beneficially owned by FMR LLC and Abigail P. Johnson
Forward-Looking Statements
- PTC Therapeutics' stock price may experience downward pressure due to FMR LLC's reduced stake. (PTC Therapeutics Inc.) — medium confidence, target: Q1 2024
FAQ
Who are the reporting persons in this SC 13G/A filing?
The reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 for both entities.
What is the CUSIP number for PTC Therapeutics Inc. common stock?
The CUSIP number for PTC Therapeutics Inc. common stock is 69366J200, as listed in the filing.
What percentage of PTC Therapeutics Inc. common stock does FMR LLC beneficially own as of this filing?
FMR LLC beneficially owns 2.404% of PTC Therapeutics Inc. common stock, as detailed in Item 11 and Item 4(b) of the filing.
What is the total number of shares beneficially owned by FMR LLC and Abigail P. Johnson?
Both FMR LLC and Abigail P. Johnson beneficially own 1,814,421 shares of PTC Therapeutics Inc. common stock, as indicated in Item 7 and Item 9 for both reporting persons.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed pursuant to Rule 13d-1(b), as indicated by the checked box in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 10, 2024 by Abigail P. Johnson regarding PTC THERAPEUTICS, INC. (PTCT).